Nuvectra Corporation (NVTR)’s Trend Up, Especially After Today’s 52-Week High Milestone

May 17, 2018 - By Ash Ash

Nuvectra Corporation (NASDAQ:NVTR) Logo

The stock of Nuvectra Corporation (NASDAQ:NVTR) hit a new 52-week high and has $18.93 target or 9.00 % above today’s $17.37 share price. The 8 months bullish chart indicates low risk for the $245.84 million company. The 1-year high was reported on May, 17 by Barchart.com. If the $18.93 price target is reached, the company will be worth $22.13 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 2.96% or $0.5 during the last trading session, reaching $17.37. About 110,155 shares traded. Nuvectra Corporation (NASDAQ:NVTR) has risen 92.78% since May 17, 2017 and is uptrending. It has outperformed by 81.23% the S&P500.

Analysts await Nuvectra Corporation (NASDAQ:NVTR) to report earnings on August, 14. They expect $-0.92 EPS, up 14.02 % or $0.15 from last year’s $-1.07 per share. After $-0.84 actual EPS reported by Nuvectra Corporation for the previous quarter, Wall Street now forecasts 9.52 % negative EPS growth.

More news for Nuvectra Corporation (NASDAQ:NVTR) were recently published by: Globenewswire.com, which released: “Nuvectraâ„¢ Reports First Quarter 2018 Financial Results” on May 02, 2018. Globenewswire.com‘s article titled: “Nuvectra to Present at Two Upcoming Investor Conferences” and published on May 17, 2018 is yet another important article.

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes its neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets in Europe. The company has market cap of $245.84 million. The firm offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs. It currently has negative earnings. It also provides neural interface systems, including microelectrode arrays, probes, and electrode instrumentation and accessories; and develops Virtis, a sacral nerve stimulation system for the treatment of chronic urinary retention and the symptoms of overactive bladder.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: